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Abstract
Background: Tuberculosis continues to be one of the leading causes of death worldwide and in the American
region. Although multidrug-resistant tuberculosis (MDR-TB) remains a threat to TB control in Panama, few studies
have focused in typing MDR-TB strains. The aim of our study was to characterize MDR Mycobacterium tuberculosis
clinical isolates using PCR-based genetic markers.
Methods: From 2002 to 2004, a total of 231 Mycobacterium tuberculosis isolates from TB cases country-wide were
screened for antibiotic resistance, and MDR-TB isolates were further genotyped by double repetitive element PCR
(DRE-PCR), (GTG)5-PCR and spoligotyping.
Results: A total of 37 isolates (0.85%) were resistant to both isoniazid (INH) and rifampicin (RIF). Among these 37
isolates, only two (5.4%) were resistant to all five drugs tested. Dual genotyping using DRE-PCR and (GTG)5-PCR of
MDR Mycobacterium tuberculosis isolates revealed eight clusters comprising 82.9% of the MDR-TB strain collection,
and six isolates (17.1%) showed unique fingerprints. The spoligotyping of MDR-TB clinical isolates identified 68% as
members of the 42 (LAM9) family genotype.
Conclusion: Our findings suggest that MDR Mycobacterium tuberculosis is highly clustered in Panama’s metropolitan
area corresponding to Panama City and Colon City, and our study reveals the genotype distribution across the country.
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Background
Mycobacterium tuberculosis (M. tuberculosis) is the bacter-
ium that causes tuberculosis (TB), which is the world’s
leading infectious killer after human immunodeficiency
virus (HIV). TB itself kills around 1.4 million people annu-
ally with virtually all deaths occurring in developing coun-
tries [1]. TB control has been impaired by the persistence
of multidrug-resistant M. tuberculosis (MDR-TB). In 2011,
Panama reported 1301 new pulmonary TB cases, including
an estimated seven MDR-TB cases [2]. The estimated aver-
age prevalence of MDR-TB in Panama for 2011 was ap-
proximately 0.5%; however, a more detailed country-wide
surveillance project is now underway [2]. Also, novel diag-
nosis and biomarker tests for monitoring the treatment re-
sponse in MDR-TB cases are currently under evaluation.
MDR-TB case surveillance and control in Panama cur-
rently rely on conventional epidemiology tools. Presently,
the health care system interviews MDR-TB-affected pa-
tients to collect demographic characteristic information, as
recommended by WHO [3]. In addition, information about
past history of TB and treatment, type and extent of dis-
ease, concomitant medical illnesses and substance abuse,
among others risk factors, is also collected. However, inves-
tigation of these MDR-TB patients’ contacts remains lim-
ited, and thus, conventional epidemiology findings are
unable to prove true links between most MDR-TB cases
[4,5]. Consequently, the National TB Program (NTBP)
continues to invest enormous time and effort to determine
transmission dynamics within communities in order to im-
plement appropriate strategies for TB and MDR-TB con-
trol and prevention.
For more than a decade, researchers have demonstrated
the use of genomic markers to study TB and MDR-TB
epidemiology as a useful strategy for understanding TB
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transmission dynamics [6]. Rapid and inexpensive genotyp-
ing based on PCR assays, such as double repetitive element
PCR (DRE-PCR) and (GTG)5, have proven to be useful in
determining the genetic relationships and epidemiology of
TB and MDR-TB within vulnerable communities; these
genotyping techniques identify and track individual M. tu-
berculosis strains [7-13]. Similarly, spoligotyping is a well-
established commercial method that provides worldwide
standardized information about M. tuberculosis isolates’
family lineage background [14-17]. However, despite these
laboratory improvements, data on the transmission and
distribution of MDR M. tuberculosis strains within Panama
remain scarce. Therefore, our study aimed to characterize
the distribution of MDR M. tuberculosis isolates from the
Republic of Panama collected between 2002 and 2004
using DRE-PCR and (GTG)5-PCR in a dual genotyping
strategy and spoligotyping.
Methods
MDR M. tuberculosis clinical isolates
M. tuberculosis isolates from 231 suspected multidrug-
resistant pulmonary TB cases were collected between
January 2002 and December 2004 from local laboratories
at nine different health centers and hospitals located
throughout the Republic of Panama. Because the strain
collection was performed as part of the Panamanian stand-
ard of patient care for TB diagnosis and control, this study
was not submitted to ethical committee evaluation. The
identification of M. tuberculosis isolates was performed
using biochemical tests including niacin, nitrate and cata-
lase tests [18]. All isolates were evaluated for antibiotic re-
sistance on Lowenstein-Jensen (LJ) medium according to
the Cannetti proportion method [19]. Briefly, a suspension
of M. tuberculosis clinical isolate was placed in an LJ tube
with and without drugs. M. tuberculosis colony forming
units (CFUs) were enumerated in the drug-free medium
(control tubes) and in the tubes with anti-tuberculosis
drugs. Each LJ media tube contained a single antibiotic at
the following concentrations: 0.2 mg/ml isoniazid (INH),
40 mg/ml rifampicin (RFP), 4 mg/ml streptomycin (SM),
2 mg/ml ethambutol (EMB) and 2 mg/ml paramino-
salicylic acid (PAS). The resistance percentage was calcu-
lated by multiplying the ratio of the CFUs in media with
drugs to the CFUs in media without drugs by 100. No
growth in the LJ medium with anti-tuberculosis drugs in-
dicated a sensitive strain. M. tuberculosis isolates that
were resistant to at least rifampicin and isoniazid were
classified as MDR M. tuberculosis and stored in 10% skim
milk (Difco, USA) at −70°C until further DNA extraction
and genotyping.
DNA isolation from MDR M. Tuberculosis clinical isolates
DNA was extracted from M. tuberculosis isolates with
Chelex® using a method described previously [20,21].
Briefly, two or three colonies were inactivated at 80°C
for 30 min in Tris-EDTA (10 mM Tris, 1 mM EDTA,
pH 7.4) buffer and then immediately placed on ice.
Then, the bacteria were centrifuged at 10,000 rpm for
two min. The supernatant was then discarded and the
pellet resuspended in 500 μl of 5% Chelex-100. The sus-
pensions were vortexed for a few seconds and incubated
at 56°C for 20 min, boiled at 100°C for 10 min. and then
placed on ice for two min. and centrifuged at 13,000 rpm
for five min. The supernatant containing the DNA was
stored at −20°C.
DRE-PCR genotyping
Isolated DNA from MDR M. tuberculosis isolates was
analyzed with a modified DRE-PCR protocol [8,10]. The
PCR assays were performed in a 25-μl reaction volume
containing three μl of the extracted DNA, Go-Taq Green
Master Mix (Promega Corporation, USA) supplemented
with 4.5 Mm MgCL2, 6% dimethyl sulfoxide (DMSO),
1 U Taq DNA polymerase (Bioselec S.A., Mexico D.F.) and
the four primers Ris1, Ris2, Pntbl and Pntb2 at 25 pmol
each as previously described [10]. The PCR was performed
as described by Friedman et al., including an additional
ramp of +0.7°C per second between the denaturation and
annealing segments [10]. PCR products were analyzed by
electrophoresis on 2% agarose gel and visualized with eth-
idium bromide in a gel documentation system (Ultra-Lum
Omega System, USA).
(GTG)5-PCR genotyping
DNA fingerprinting of MDR M. tuberculosis was carried
out using a modification of previously described protocols
[12,22]. Briefly, DNA samples from MDR M. tuberculosis
strains were subjected to rep-PCR using the (GTG)5
primer (5′-GTGGTGGTGGTGGTG-3′). The PCR assays
were performed in a 50-μl reaction volume containing
10 ng of genomic DNA, one unit of Taq DNA polymerase
(Roche, Mannheim, Germany), 0.8 mM of the (GTG)5
primer (Sigma-Aldrich, St. Louis, MO), 1.5 mM MgCl2
and 200 μM of each deoxynucleoside triphosphate (Roche,
Mannheim, Germany). PCR cycling conditions consisted
of initial activation at 94°C for five min, followed by 35 -
cycles of a three-step PCR program (94°C for 45 seconds,
40°C for one min. and 65°C for 10 min.) and a final exten-
sion at 65°C for 20 min. PCR products were analyzed by
electrophoresis on 1.2% agarose gel and visualized with
ethidium bromide.
Spoligotyping genotyping
Spoligotyping was performed on genomic DNA using
the standard method described by Kamerbeek et al. [14].
Spoligotypes were reported in standard international type
number (SIT) and octal code numbers were obtained from
the SPOLDB4.0 [23].
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Data analysis
The fingerprints obtained using both DRE-PCR and
(GTG)5-PCR were analyzed using Bionumerics Software
version 6.6 (Applied Maths, Sint-Martens-Latem, Belgium).
Band patterns were evaluated using the Dice similarity co-
efficient with a 4% band tolerance and 1% of optimization.
Dendograms were constructed using the unweighted pair
group method with arithmetic mean (UPGMA). Related
strains in a cluster were defined as having more than 90%
of homology. The similarity between (GTG)5-PCR and
DRE-PCR was calculated using the Pearson correlation co-
efficient (r value) using Bionumerics Software.
Results
From 2002 to 2004, the Panamanian NTBP reported a
total of 4507 new pulmonary TB cases country-wide. Of
those new cases, 231M. tuberculosis clinical isolates
were sent to Laboratorio Central de Referencia de Salud
Pública de Instituto Conmemorativo Gorgas de Estudios
de la Salud (LCRSP-ICGES) for drug susceptibility test-
ing (DST). At least 69% (160) of these isolates were ori-
ginally obtained from the metropolitan region, including
San Miguelito, Panama Este, Panama Oeste and Colon
City. The DST results revealed monoresistance to INH
(29.0%), RFP (30.7%), SM (22.1%), EMB (8.2%) and PAS
(0.9%) in the collection of 231M. tuberculosis isolates.
Thirty-seven isolates collected between 2002 and 2004
demonstrated resistance to at least INH and RFP, and
these isolates were defined as MDR Mycobacterium tu-
berculosis. Thus, an average prevalence for the three-
year period is estimated at 0.82% of the total national
TB cases reported (Figure 1). These 37 MDR M. tuber-
culosis isolates were not distributed uniformly across
Panama. Colon City itself accounted for 40% of the
MDR-TB cases, whereas Chiriqui and the Metropolitana
region accounted for 23% and 20%, respectively (Table 1).
Within these 37 MDR-TB isolates, 76% (28 isolates)
were resistant to INH, RIF and SM. Only 5.4% (two iso-
lates) of the MDR-TB isolates showed resistance to all
five drugs
The combined analysis of DRE-PCR and (GTG)5-PCR
showed a high clustering of MDR M. tuberculosis clin-
ical isolates in the Colon and Metropolitana regions of
Panama. Fourteen different DRE-PCR patterns were
obtained with a range of two to eight bands. In contrast,
(GTG)5-PCR showed six different patterns with a range
of eight to fifteen bands. Two MDR M. tuberculosis
isolates did not amplify and were excluded from the
clustering computer analysis (Figure 2). A comparison be-
tween both methods revealed only a 15.3% correlation
(Pearson p = 0.0424). Therefore, we assigned a genotype to
each strain using both methods in a dual typing strategy.
The dual genotyping identified Cluster A, which consisted
of six out of the 35 isolates (17.1%). In this cluster, four
strains were isolated from Colon City and one was isolated
from Chiriqui. Cluster B included eight isolates (22.9%), six
from Colon City, one from the Metropolitana region and
one from San Miguelito. Cluster C consisted of four iso-
lates (11.4%) from our MDR M. tuberculosis set. This clus-
ter was composed of three isolates from the Metropolitana
region and one from Chiriqui. Cluster G included 5.7%
(2/35) of MDR M. tuberculosis isolates, both from patients
from the Colon region. Cluster H contained three out of
the 35 isolates (8.6%). Clusters I and J consisted of two iso-
lates each (5.7%), of which all four MDR M. tuberculosis
cases were from the Chiriqui region. Finally, Cluster L in-
cluded two isolates from Panama Este and two isolates
from Panama Oeste. Six MDR M. tuberculosis isolates
(17.1%) were not grouped into the clusters described above
(Figure 2).
The spoligotyping analysis typed almost 68% of MDR
M. tuberculosis isolates as members of the 42 (LAM9)
family. Remaining MDR-M. tuberculosis isolates were
classified as spoligo international type (SIT) numbers 68,
46, 119, and 1366 according to the SPOLDB4.0 Inter-
national Database (Table 1) [23]. We identified two
MDR M. tuberculosis isolates that were not annotated in
this database.
Discussion
During the 2002–2004 period, a collection of 231M. tuber-
culosis isolates were identified to have monoresistance to
INH (29.0%), RFP (30.7%), SM (22.1%), EMB (8.2%) or
Figure 1 Proportion of MDR-TB cases in Panama from 2002 to
2004. Country-wide M. tuberculosis clinical isolates were evaluated
by the Canetti drug susceptibility test between 2002 and 2004.
Thirty-seven isolates were multidrug-resistant (MDR). The bars show
the percentage of MDR M. tuberculosis strains per year. The dotted
line indicates the countrywide average proportion of TB cases with
MDR-TB for the three-year period.
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Table 1 Resistance and genotype profiles of MDR M. tuberculosis clinical isolates in Panama 2002-2004
Region N (%) Resistance profiles DRE-(GTG)5 clusters Spoligo international types
Colon 15 (40.5) a, b, c A, B, G, K 42, 46, 68
Chiriqui 10 (27.0) a, b, c A, C, D, F, H, I, J 42, 119, unknown
Metropolitana 5 (13.5) a, b B, C 42, 68
Panama Oeste 2 (5.4) b L, E 46
San Miguelito 2 (5.4) a, b B, M 42, 1366
Panama Este 1 (2.7) b L 119
Changuinola 1 (2.7) a H 17
Veraguas 1 (2.7) a N 42
Note: Resistance profiles are classified as follows: a) INH, RFP; b) INH, RFP, SM; c) INH, RFP, SM, EMB.
Figure 2 Combined dendogram based on DRE-PCR and (GTG)5 genotyping. Genomic DNA was extracted from MDR M. tuberculosis strains
and amplified by multiplex (GTG)5-PCR and DRE-PCR. Dendograms were built using the Dice coefficient at 4% band tolerance and 1%
optimization. The correlation for each band is shown at the top of the figure.
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PAS (0.9%). Thirty-seven (0.82%) of these isolates were rec-
ognized as MDR M. tuberculosis because they were resist-
ant to both INH and RFP drugs. Among these MDR
M. tuberculosis isolates, two (5.4%) were resistant to all five
drugs. Our study results show that nearly 83% of these
MDR M. tuberculosis cases were grouped within Panama
City and Colon City, indicating a higher clustering rate
compared to other cities in the Latin American region,
such as 39.4% reported in Havana and 55.3% reported in
Rio de Janeiro [8,24]. Specific molecular cluster patterns
were found to be prevalent in Colon, San Miguelito and
the Metropolitana region within the Republic of Panama.
Colon City harbored the two largest clusters identified in
this strain collection (Cluster A and B). Similarly, the MDR
M. tuberculosis strains recovered from the Chiriqui region
were clustered. These findings suggest that these MDR
M. tuberculosis strains were spread rapidly during the
period from 2002 to 2004.
Our data indicate that the Colon region has the highest
number of clustered MDR M. tuberculosis isolates. One
plausible explanation is the high TB incidence rate, which
reached nearly 100/100,000 inhabitants in Colon during
the study period [25]. In addition, the HIV-TB coinfection
rate was up to 40% during those years. These two fac-
tors combined with Colon’s lower socioeconomic status,
extreme poverty levels and overcrowded living condi-
tions might favor the transmission of MDR M. tubercu-
losis strains. New collaborative interventions to reinforce
the TB-HIV response are currently being implemented
by health authorities, INDICASAT-AIP and University
Research Co., LLC (URC-CHS) to limit this situation,
not only in Colon but across the entire Republic of
Panama.
The overall high clustering rate found in our study in-
dicates the possibility that patients belonging to a cluster
might have been infected with an M. tuberculosis strain
that easily became resistant. Another possible explan-
ation is that an MDR M. tuberculosis mutant strain was
selected by mono-therapy or irregular treatment com-
pliance [26]. The exact reason for our findings remains
to be explored by further combining bacterial genomics
and patient epidemiological data. A recent study dem-
onstrated the distribution of point mutations conferring
resistance in a collection of MDR M. tuberculosis iso-
lates from Panama using a multiplex PCR platform
[27]. This study revealed that the most frequent point
mutation is located in codon 315 of the KatG gene.
However, it is expected that MDR M. tuberculosis iso-
lates with a KatG gene mutation are likely to be clus-
tered [28]. Molecular epidemiology studies using whole
genome sequencing or VNTR-MIRU are now required
to determine the extent of MDR-TB transmission and
monitor the expansion of this infection, especially in
the Colon region [29,30].
The study of MDR-TB cases in Panama currently uses
conventional epidemiology tools. The contact investiga-
tions for these MDR-TB cases remain limited, and con-
ventional epidemiology results are unable to prove true
links between most MDR-TB cases [4,5]. The use of
PCR-based genotyping tools, such as those used in the
present study, might be helpful in conducting the epi-
demiological contact investigation of MDR-TB cases in
Panama [8,10,11]. Although DRE-PCR showed a poor cor-
relation with (GTG)5 patterns in our study, a dual geno-
typing strategy using both techniques increased the
accuracy when analyzing our MDR M. tuberculosis strain
collection. Because the cost of PCR and primers has de-
creased, this dual strategy might be useful in settings with-
out access to more expensive, cutting edge technologies.
The reasons for the persistence of MDR M. tubercu-
losis strains in Panama remain unknown. One explan-
ation might be stochastic introduction resulting from
migration for the Panama Canal construction at the end
of the nineteenth century. Other plausible explanations
include malnutrition, lack of adherence to anti-TB ther-
apy and/or the intermittent availability of drugs. As
depicted in our study, the spoligotype 42 (LAM9) was
present in almost 68% of the MDR M. tuberculosis
isolates studied. Despite Panama’s geographical proxim-
ity to Valle de Cauca, Colombia, we did not find Beijing
genotypes in the MDR-TB isolates from Panama [31].
Similarly, other studies in America have found wider
genetic diversity when genotyping MDR M. tuberculosis
strains using spoligotyping [15-17]. Our sample collec-
tion was not created under a systematic national MDR
surveillance program; however, the findings indicate a
need to redirect efforts in order to understand the trans-
mission dynamics of MDR M. tuberculosis strains.
Conclusion
The findings presented here reveal that most MDR
M. tuberculosis strains isolated from Panama City and
Colon City are highly clustered. Our study confirmed the
clustering of a limited number of MDR-TB cases using an
inexpensive dual genotyping strategy; this strategy could be
extended to countrywide MDR surveillance to gain a better
understanding of MDR-TB transmission dynamics and
contribute to MDR-TB control in the short term.
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